Why the study?
Does transdermal hormone replacement therapy prevent admission to hospital with unstable angina, myocardial infarction, or cardiac death in postmenopausal women with angiographically proven ischaemic heart disease?
Does transdermal hormone replacement therapy prevent admission to hospital with unstable angina, myocardial infarction, or cardiac death in postmenopausal women with angiographically proven ischaemic heart disease?
Transdermal hormone replacement therapy does not provide secondary cardiovascular prevention benefits in postmenopausal women with ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Transdermal HRT should not be used for secondary cardiovascular prevention; confirms lack of benefit in postmenopausal women with established IHD.
Clarke et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: